Dermatomiosite

Drake LA, Dinehart SM, Farmer ER, et al; American Academy of Dermatology. Guidelines of care for dermatomyositis. J Am Acad Dermatol. 1996 May;34(5 Pt 1):824-9. Resumo

Bruschi F, Murrell KD. New aspects of human trichinellosis: the impact of new trichinella species. Postgrad Med J. 2002 Jan;78(915):15-22.Texto completo  Resumo

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 Feb 20;292(8):403-7. Resumo

2. Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006 Apr;54(4):597-613. Resumo

3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003 Sep 20;362(9388):971-82. Resumo

4. Sigurgeirsson B, Lindelof B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med. 1992 Feb 6;326(6):363-7. Resumo

5. Medsger TA, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715-723. Resumo

6. Kurland LT, Hauser WA, Ferguson RH, et al. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc. 1969;44:649-663. Resumo

7. Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329-1334. Resumo

8. Vargas-Leguas H, Selva-O'Callaghan A, Campins-Marti M, et al. Polymyositis-dermatomyositis: incidence in Spain (1997-2004). Medicina Clinica. 2007;129:721-724. [In Spanish] Resumo

9. Klippel JH, Dieppe PA. Rheumatology. 2nd ed. London, UK: Mosby; 1997.

10. Caro I. Dermatomyostis. Semin Cutan Med Surg. 2001 Mar;20(1):38-45. Resumo

11. Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999 May;78(3):139-47. Resumo

12. Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol. 2002;14:658-662. Resumo

13. Mendez E, Lipton R, Dyer A, et al. The incidence of juvenile dermatomyositis (JDM): results from the NIAMS JDM research registry. Arthritis Rheum. 1999;42:S300.

14. Christopher-Stine L, Plotz PH. Myositis: an update on pathogenesis. Curr Opin Rheumatol. 2004 Nov;16(6):700-6. Resumo

15. Goldstein R, Duvic M, Targoff IN, et al. HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum. 1990;33:1240-1248. Resumo

16. Okada S, Weatherhead E, Targoff IN, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003 Aug;48(8):2285-93.Texto completo  Resumo

17. Reimers CD, Pongratz DE, Neubert U, et al. Myositis caused by Borrelia burgdorferi: report of four cases. J Neurol Sci. 1989 Jun;91(1-2):215-26. Resumo

18. Magid SK, Kagen LJ. Serologic evidence for acute toxoplasmosis in polymyositis-dermatomyositis. Increased frequency of specific anti-toxoplasmosa IgM antibodies. Am J Med. 1983 Aug;75(2):313-20. Resumo

19. Travers RL, Hughes GR, Cambridge G, et al. Coxsackie B neutralisation titres in polymyositis/dermatomyositis. Lancet. 1977 Jun 11;1(8024):1268. Resumo

20. Christensen ML, Pachman LM, Schneiderman R, et al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986 Nov;29(11):1365-70. Resumo

21. Pearson CM. Editorial: Myopathy with viral-like structures. N Engl J Med. 1975 Mar 20;292(12):641. Resumo

22. Bowles NE, Dubowitz V, Sewry CA, et al. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet. 1987 May 2;1(8540):1004-7. Resumo

23. Rosenberg NL, Rotbart HA, Abzug MJ, et al. Evidence for a novel picornavirus in human dermatomyositis. Ann Neurol. 1989 Aug;26(2):204-9. Resumo

24. Yousef GE, Isenberg DA, Mowbray JF. Detection of enterovirus specific RNA sequences in muscle biopsy specimens from patients with adult onset myositis. Ann Rheum Dis. 1990 May;49(5):310-5.Texto completo  Resumo

25. Simpson NB, Golding JR. Dermatomyositis induced by penicillamine. Acta Derm Venereol. 1979;59(6):543-4. Resumo

26. Fernandes L, Swinson DR, Hamilton EB. Dermatomyositis complicating penicillamine treatment. Ann Rheum Dis. 1977 Feb;36(1):94-5.Texto completo  Resumo

27. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003 Mar;48(3):439-41. Resumo

28. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol. 1994 Feb;33(2):199. Resumo

29. Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J. 1996 Nov;72(853):694.Texto completo  Resumo

30. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med. 1995 Dec;25(6):745-6. Resumo

31. Thual N, Penven K, Chevallier JM, et al. Fluvastatin-induced dermatomyositis [in French]. Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):996-9. Resumo

32. Curran JJ, Jamieson TW. Dermatomyositis-like syndrome associated with phenylbutazone therapy. J Rheumatol. 1987 Apr;14(2):397-8. Resumo

33. Magro CM, Schaefer JT, Waldman J, et al. Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. J Cutan Pathol. 2008 Jan;35(1):74-81. Resumo

34. Greenberg SA, Amato AA. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol. 2004;17:359-364. Resumo

35. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314:329-334. Resumo

36. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov;28(4):779-98, vi. Resumo

37. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991 Nov 21;325(21):1487-98. Resumo

38. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol. 1995 May;37 Suppl 1:S74-86. Resumo

39. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008-2019. Resumo

40. Costner MI, Jacobe H. Dermatopathology of connective tissue diseases. Adv Dermatol. 2000;16:323-360. Resumo

41. Harati Y, Niakan E, Bergman EW. Childhood dermatomyositis in monozygotic twins. Neurology. 1986 May;36(5):721-3. Resumo

42. Leonhardt T. Familial occurrence of collagen diseases. II. Progressive systemic sclerosis and dermatomyositis. Acta Med Scand. 1961 Jun;169:735-42. Resumo

43. Walker GL, Mastaglia FL, Roberts DF. A search for genetic influence in idiopathic inflammatory myopathy. Acta Neurol Scand. 1982 Oct;66(4):432-43. Resumo

44. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997 Jul;40(7):1257-66. Resumo

45. Rider LG, Shamim E, Okada S, et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum. 1999 Jun;42(6):1285-90.Texto completo  Resumo

46. Hassan AB, Nikitina-Zake L, Sanjeev CB, et al. Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum. 2004 Mar;50(3):1013-5.Texto completo  Resumo

47. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov;28(4):891-916. Resumo

48. Werth VP, Callen JP, Ang G, et al. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol. 2002 Sep;119(3):617-20. Resumo

49. Sontheimer RD. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem Photobiol. 1996 May;63(5):583-94. Resumo

50. Werth VP, Bashir M, Zhang W. Photosensitivity in rheumatic diseases. J Investig Dermatol Symp Proc. 2004 Jan;9(1):57-63. Resumo

51. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature. 1983 Jul 14-20;304(5922):177-9. Resumo

52. Dalakas MC, Pezeshkpour GH, Gravell M, et al. Polymyositis associated with AIDS retrovirus. JAMA. 1986 Nov 7;256(17):2381-3. Resumo

53. Wrzolek MA, Sher JH, Kozlowski PB, et al. Skeletal muscle pathology in AIDS: an autopsy study. Muscle Nerve. 1990 Jun;13(6):508-15. Resumo

54. Albert JM, Ott HJ. Calcifying dermatomyositis following antitentanus vaccination. Arch Int Med. 1983 Jul;143(7):1457-8. Resumo

55. Kass E, Straume S, Mellbye OJ, et al. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol. 1979;8(3):187-91. Resumo

56. Ehrengut W. Dermatomyositis and vaccination. Lancet. 1978 May 13;1(8072):1040-1. Resumo

57. Cotterill JA, Shapiro H. Dermatomyostis after immunisation. Lancet. 1978 Nov 25;2(8100):1158-9. Resumo

58. Sontheimer R, Provost T. Cutaneous manifestations of rheumatic diseases. 2nd ed. Philidelphia: Lippencott, William & Wilkins; 2004.

59. Rockerbie NR, Woo TY, Callen JP, et al. Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol. 1989 Apr;20(4):629-32. Resumo

60. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol. 2003 Nov;15(6):714-22. Resumo

61. Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341-51. Resumo

62. Cheong WK, Hughes GR, Norris PG, et al. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994 Aug;131(2):205-8. Resumo

63. Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004 May;29(3):273-6. Resumo

64. Rosenberg NL, Carry MR, Ringel SP. Association of inflammatory myopathies with other connective tissue disorders and malignancies. In: Dalakas MC, ed. Polymyositis and Dermatomyositis. Stoneham, MA: Butterworth; 1988:37-69.

65. Koler RA, Montemarano A. Dermatomyositis. Am Fam Physician. 2001 Nov 1;64(9):1565-72.Texto completo  Resumo

66. Callen JP. Dermatomyositis. Lancet. 2000 Jan 1;355(9197):53-7. Resumo

67. Ohtsuka T. The relation between nailfold bleeding and capillary microscopic abnormality in patients with connective tissue diseases. Int J Dermatol. 998 Jan;37(1):23-6. Resumo

68. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum. 1973 Sep-Oct;16(5):619-28. Resumo

69. Blane CE, White SJ, Braunstein EM, et al. Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol. 1984 Feb;142(2):397-400.Texto completo  Resumo

70. Cohen MG, Nash P, Webb J. Calcification is rare in adult-onset dermatopolymyositis. Clin Rheumatol. 1986 Dec;5(4):512-6. Resumo

71. Marie I, Hatron PY, Hachulla E, et al. Pulmonary involvement in polymyositis and dermatomyositis. J Rheumatol. 1998 Jul;25(7):1336-43. Resumo

72. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol. 1996 Jul-Aug;14(4):373-9. Resumo

73. Riemekasten G, Opitz C, Audring H, et al. Beware of the heart: the multiple picture of cardiac involvement in myositis. Rheumatology (Oxford). 1999 Nov;38(11):1153-7.Texto completo  Resumo

74. Schumacher HR, Schimmer B, Gordon GV, et al. Articular manifestations of polymyositis and dermatomyositis. Am J Med. 1979 Aug;67(2):287-92. Resumo

75. Bunch TW, O'Duffy JD, McLeod RA. Deforming arthritis of the hands in polymyositis. Arthritis Rheum. 1976 Mar-Apr;19(2):243-8. Resumo

76. Jorizzo J. Dermatomyositis: practical aspects. Arch Dermatol. 2002 Jan;138(1):114-6. Resumo

77. Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol. 1998 Mar;38(3):397-404. Resumo

78. Stonecipher MR, Jorizzo JL, White WL, et al. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis? J Am Acad Dermatol. 1993 Jun;28(6):951-6. Resumo

79. Amoura Z, Duhaut P, Huong DL, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1279-82.Texto completo  Resumo

80. Provost TT, Flynn JA. Dermatomyositis. In: Provost TT, Flynn JA, eds. Cutaneous medicine. Hamilton, Ontario, Canada: B.C. Decker Inc; 2001:82-103.

81. Drake LA, Dinehart SM, Farmer ER, et al; American Academy of Dermatology. Guidelines of care for dermatomyositis. J Am Acad Dermatol. 1996 May;34(5 Pt 1):824-9. Resumo

82. Sparsa A, Liozon E, Herrmann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol. 2002 Jul;138(7):885-90.Texto completo  Resumo

83. Martin L, Chalmers IM, Dhingra S, et al. Measurements of maximum respiratory pressures in polymyositis and dermatomyositis. J Rheumatol. 1985;12:104-107. Resumo

84. Haupt HM, Hutchins GM. The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am J Cardiol. 1982 Nov;50(5):998-1006. Resumo

85. Stern R, Godbold JH, Chess Q, et al. ECG abnormalities in polymyositis. Arch Intern Med. 1984 Nov;144(11):2185-9. Resumo

86. Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo-1 autoantibodies: an evolving spectrum of disease manifestations. Clin Rheumatol. 2000;19(5):371-7. Resumo

87. Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology. 2001;202:123-126. Resumo

88. Basset-Seguin N, Roujeau JC, Gherardi R, et al. Prognostic factors and predictive signs of malignancy in adult dermatomyositis: a study of 32 cases. Arch Dermatol. 1990;126:633-637. Resumo

89. Vignos PJ, Goldwyn J. Evaluation of laboratory tests in diagnosis and management of polymyositis. Am J Med Sci. 1972 Apr;263(4):291-308. Resumo

90. Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum. 1987 Feb;30(2):213-7. Resumo

91. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation: a poor prognostic sign. Am J Med. 1986 Feb;80(2):329-32. Resumo

92. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy: a useful diagnostic and assessment tool. J Rheumatol. 2001 Jul;28(7):1591-9. Resumo

93. Kagen LJ. Polymyositis/dermatomyositis. In: McCarty DJ, ed. Arthritis and allied conditions. 11th ed. Philadelphia, PA: Lea and Febiger; 1989:1092-1117.

94. Adams EM, Chow CK, Premkumar A, et al. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics. 1995 May;15(3):563-74.Texto completo  Resumo

95. Schweitzer ME, Fort J. Cost-effectiveness of MR imaging in evaluating polymyositis. AJR Am J Roentgenol. 1995 Dec;165(6):1469-71.Texto completo  Resumo

96. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990 Apr;27(4):343-56. Resumo

97. Barkhaus PE, Nandedkar SD, Sanders DB. Quantitative EMG in inflammatory myopathy. Muscle Nerve. 1990 Mar;13(3):247-53. Resumo

98. Uncini A, Lange DJ, Lovelace RE, et al. Long-duration polyphasic motor unit potentials in myopathies: a quantitative study with pathological correlation. Muscle Nerve. 1990 Mar;13(3):263-7. Resumo

99. Janis JF, Winkelmann RK. Histopathology of the skin in dermatomyositis. Arch Dermatol. 1968 Jun;97(6):640-50. Resumo

100. Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum. 1984 Oct;27(10):1150-6. Resumo

101. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol. 2004 Nov;16(6):692-9. Resumo

102. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine. 1991 Nov;70(6):360-74. Resumo

103. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004 Mar;63(3):297-301.Texto completo  Resumo

104. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996 Aug;26(1):459-67. Resumo

105. Seelig HP, Moosbrugger I, Ehrfeld H, et al. The major dermatomyositis-specific autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum. 1995 Oct;38(10):1389-99. Resumo

106. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985 Jul;28(7):796-803. Resumo

107. Jablonska S, Blaszyk M. Scleromyositis (scleroderma/polimyositis overlap) is an entity. J Eur Acad Dermatol Venereol. 2004 May;18(3):265-6. Resumo

108. Tomasova Studynkova J, Charvat F, Jarosova K, et al. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford). 2007 Jul;46(7):1174-9.Texto completo  Resumo

109. Brownlow K, Elevitch FR. Serum creatine phosphokinase isoenzyme (CPK2) in myositis. JAMA. 1974 Nov 25;230(8):1141-4. Resumo

110. Hughes M, Lilleker JB, Herrick AL, et al. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Ann Rheum Dis. 2015 May;74(5):795-8.Texto completo  Resumo

111. Padley SP, Hansell DM, Flower CD, et al. Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin Radiol. 1991 Oct;44(4):222-6. Resumo

112. Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol. 2004 Mar;49(3):235-44. Resumo

113. de Merieux P, Verity MA, Clements PJ, et al. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum. 1983 Aug;26(8):961-8. Resumo

114. Bruschi F, Murrell KD. New aspects of human trichinellosis: the impact of new trichinella species. Postgrad Med J. 2002 Jan;78(915):15-22.Texto completo  Resumo

115. Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve. 2001 Nov;24(11):1562-6. Resumo

116. Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003 Oct;16(5):569-75. Resumo

117. Chérin P, Herson S, Wechsler B, et al. Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis: an open trial in 15 patients [in French]. Presse Med. 1991 Feb 16;20(6):244-9. Resumo

118. Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol. 1979 Oct;115(10):1251-2. Resumo

119. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993 Apr;94(4):379-87. Resumo

120. Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol. 1991 Nov-Dec;9(6):658-9. Resumo

121. Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995 Apr;1(2):99-102. Resumo

122. Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974 Aug;81(2):182-9. Resumo

123. Mastaglia FL, Garlepp MJ, Phillips BA, et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve. 2003 Apr;27(4):407-25. Resumo

124. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000 Dec;27(12):2855-9. Resumo

125. Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J. 2006 Jul;82(969):417-24. Resumo

126. Correia O, Polonia J, Nunes JP, et al. Severe acute form of adult dermatomyositis treated with cyclosporine. Int J Dermatol. 1992 Jul;31(7):517-9. Resumo

127. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989 May 13;1(8646):1063-6. Resumo

128. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000 Jun;27(6):1542-5. Resumo

129. Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006 Jan;142(1):65-9.Texto completo  Resumo

130. Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006 Jun;8(3):167-73. Resumo

131. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985 Dec;12(6):1140-8. Resumo

132. Leroy JP, Drosos AA, Yiannopoulos DI, et al. Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome. Arthritis Rheum. 1990 Oct;33(10):1579-81. Resumo

133. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993 Mar;36(3):319-24. Resumo

134. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993 Dec 30;329(27):1993-2000.Texto completo  Resumo

135. Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol. 2006 Apr;6(4):550-6. Resumo

136. Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol. 1999 Jul;26(7):457-9. Resumo

137. Peake MF, Perkins P, Elston DM, et al. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis. 1998 Aug;62(2):89-93. Resumo

138. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002 Jan;61(1):37-41.Texto completo  Resumo

139. Chérin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991 Aug;91(2):162-8. Resumo

140. Chérin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002 Feb;46(2):467-74. Resumo

141. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138-41. Resumo

142. Department of Health. Clinical guidelines for immunoglobulin use, 2nd ed. update. August 2011 [internet publication].Texto completo

143. Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol. 1998 Dec;39(6):899-920; quiz 921-2. Resumo

144. Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother. 2004 May;5(5):1083-99. Resumo

145. Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984 Apr;10(4):592-600. Resumo

146. James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxychloroquine. J Rheumatol. 1985 Dec;12(6):1214-6. Resumo

147. Cox NH. Amyopathic dermatomyositis, photosensitivity, and hydroxychloroquine. Br J Dermatol. 1995 Jun;132(6):1016-7. Resumo

148. Van Beek MJ, Piette WW. Antimalarials. Dermatol Clin. 2001 Jan;19(1):147-60, ix. Resumo

149. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis. Arch Dermatol. 2005 Jul;141(7):855-9.Texto completo  Resumo

150. Ueda M, Makinodan R, Matsumura M, et al. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol. 2003 Mar;148(3):595-6. Resumo

151. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004 Jan;15(1):35-9. Resumo

152. Soter NA, Fleishcer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001 Jan;44(1 Suppl):S39-46. Resumo

153. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997 Jan;36(1):67-71. Resumo

154. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996 May;39(5):723-31. Resumo

155. Villalba L, Adams EM. Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol. 1996 Nov;8(6):544-51. Resumo

156. Kissel JT, Levy RJ, Mendell JR, et al. Azathioprine toxicity in neuromuscular disease. Neurology. 1986 Jan;36(1):35-9. Resumo

157. Baudard M, Vincent A, Moreau P et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002 Sep;30(5):287-95.Texto completo  Resumo

158. Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95-102. Resumo

159. Danko K, Szegedi G. Cyclosporin A treatment of dermatomyositis. Arthritis Rheum. 1991 Jul;34(7):933-4. Resumo

160. Pugh MT, Collins NA, Rai A, et al. A case of adult dermatomyositis treated with cyclosporin A. Br J Rheumatol. 1992 Dec;31(12):855. Resumo

161. Maeda K, Kimura R, Komuta K, et al. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol. 1997;26(1):24-9. Resumo

162. Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994 Jul;19(4):367. Resumo

163. Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol. 2002 Mar;41(3):182-4. Resumo

164. Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999 Feb;21(2):319-30. Resumo

165. Hess CW, Hunziker T, Kupfer A, et al. Thalidomide-induced peripheral neuropathy: a prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol. 1986 Apr;233(2):83-9. Resumo

166. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001 Jan;19(1):79-86, viii. Resumo

167. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008 Mar;35(3):438-44. Resumo

168. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Opthamology. Ophthalmology. 2002 Jul;109(7):1377-82. Resumo

169. Marmor MF. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum. 2003 Jun;48(6):1764.Texto completo  Resumo

170. Bloom BJ, Tucker LB, Klein-Gitelman M, et al. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol. 1994 Nov;21(11):2171-2. Resumo

171. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002 Sep;138(9):1231-3; discussion 1233. Resumo

172. Rhodes LE, Tingle MD, Park BK, et al. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol. 1995 Feb;132(2):257-62. Resumo

173. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005 Feb;52(2):601-7.Texto completo  Resumo

174. Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009 Nov-Dec;27(6):1009-16. Resumo

175. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow up. Eur Neurol. 2004;52(1):61-3. Resumo

176. Miller M, Mendez E, Klein-Gitelman M, et al. Use of etanercept in juvenile dermatomyositis. Arthritis Rheum. 2002;46:S306.

177. Saadeh C. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy. Arthritis Rheum. 2000;43:193.

178. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford). 2004 Apr;43(4):524-6.Texto completo  Resumo

179. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S139-42. Resumo

180. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2237. Resumo

181. Maugar YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263-274. Resumo

182. Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22-26.Texto completo  Resumo

183. Caproni M, Cardinali C, Parodi A, et al. Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. Arch Dermatol. 2002;138:23-27.Texto completo  Resumo

184. el-Azahary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46:560-565. Resumo

185. Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol. 1994;21:643-648. Resumo

186. Carpenter JR, Bunch TW, Engel AG, et al. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol. 1977;4:207-214. Resumo

187. Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35-42. Resumo

188. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001 Jun 19;134(12):1087-95. Resumo

189. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001 Jul 6;85(1):41-5.Texto completo  Resumo

190. Chow WH, Gridley G, Mellemkjaer, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995 Jan;6(1):9-13. Resumo

191. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001 Jan 13;357(9250):96-100. Resumo

192. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore). 1994 May;73(3):153-60. Resumo

193. Tazelaar HD, Viggiano RW, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990 Mar;141(3):727-33. Resumo

194. Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999 May 22;353(9166):1762-3. Resumo

195. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005 Aug;52(8):2439-46.Texto completo  Resumo

196. Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005 Sep-Oct;23(5):707-10. Resumo

197. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005 Aug;38(5):383-92. Resumo

198. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007 Jan;46(1):124-30.Texto completo  Resumo

199. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004 Feb;43(2):143-7.Texto completo  Resumo

200. Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum. 1984 Aug;14(1):60-76. Resumo

201. Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord. 2005 Jan;15(1):32-9. Resumo

202. Viguier M, Fouere S, de la Salmoniere P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore). 2003 Mar;82(2):82-6. Resumo

203. Bowyer SL, Blane CE, Sullivan DB, et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983 Dec;103(6):882-8. Resumo

204. Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol. 1998 Nov;25(11):716-20. Resumo

205. Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford). 2000 Mar;39(3):333-4.Texto completo  Resumo

206. Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminium hydroxide therapy. Arch Dermatol. 1988 Nov;124(11):1721-2. Resumo

207. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001 May;138(5):763-6. Resumo

208. Harel L, Harel G, Korenreich L, et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phophorus metabolism in the development of calcifications. J Rheumatol. 2001 May;28(5):1129-32. Resumo

209. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.Texto completo  Resumo